Ysios Capital

#PortfolioNews I Our #portfolio company, Xeltis, has been granted FDA - La Administración de Alimentos y Medicamentos Breakthrough Device Designation for aXessTM. 🎯 aXess is a restorative conduit which enables the creation of a new, long-term living vessel for hemodialysis vascular access. ✅ This designation highlights aXess’s potential to significantly improve the lives of patients with end-stage renal disease by providing a more effective, long-lasting solution compared to current therapies. ✅ First patient treated in US pivotal trial, marking significant clinical milestone. 👉 Full details : https://bit.ly/4er7Hsp #MedTech #Innovation #Dialysis #FDA #Breakthrough #vc #YsiosPortfolio

#SPEAKER I We’re thrilled to share that Raúl Martín-Ruiz, Partner at Ysios Capital, will be speaking today at the Brain Innovation Days congress. 📢 Join Raúl and esteemed panelists for an insightful session on advancing brain health innovation under the #EUBiotechnologyAct! 🌍 "Navigating EU Policy to Accelerate #Innovation in #BrainHealth." 🧠 🗓 14 November ⏰ 14:15 - 15:00 CET 🎙 Featured Speakers - Raúl Martín-Ruiz, Partner at Ysios Capital - Frank Heemskerk , Serial Entrepreneur, CEO & Founder, Research & - Innovation Management Services bvba - Christian Suojanen, Expert in Biotech Innovation, Broadreach Global For those passionate about the future of brain health and biotech in #Europe, this panel is a must-attend! #BrainInnovationDays #Biotech #Neuroscience #EUInnovation #BrainHealth #Science #EURegulations #LifeSciences #CNS

#SPEAKER I 🌍 Demo Day: Investing Beyond Borders 🌍Join us for an exclusive online event featuring our Managing Partner Joël Jean-Mairet by Capital Cell 🗓 Date: Wednesday, November 13 ⏰ Time: 18:00h - 19:15h CET ✍ register now!! ➡ https://lu.ma/peuenyq5 🎙 Panel discussion: "Barriers to Biotech Investment in Europe: An Investor's Perspective", Joël Jean-Mairet, Partner at Ysios Capital Joana Cartocci, BoD Member at France Biotech Montserrat Corominas Flores, Founder & CEO at Intergroup Partners. 🚀 Pitch to Investor - European investment opportunities in #biotech, #healthtech, and #LifeSciences: OxyPrem AG VERIGRAFT ARJUNA Therapeutics U-Care Medical MATRIA Health Technologies EKTAH ZeCardio Therapeutics #DemoDay #InvestingBeyondBorders #Biotech #HealthTech #LifeSciences #Innovation #InvestmentOpportunities #vc

🎙#Podcast I 🚨 Mañana es el gran día: #EleccionesEEUU 2024 🚨 💥 ¿Qué significa esto para el futuro #biotech y #pharma? 💥 En el nuevo episodio de📡PÍLDORAS DE BIOTECH 💊 Enric Miquel de Pharma New Talent y Jordi Xiol te traen un análisis único sobre cómo estas elecciones podrían transformar el mercado global de #salud. 🌎 ¿Sabías que EE. UU. representa casi el 50% del #mercado #farmacéutico mundial? Este momento histórico podría redefinir la industria en temas clave como la propiedad intelectual, las políticas de #Medicare y la regulación sanitaria. 🚀  ¡No te pierdas este análisis a fondo!  Dale play y descubre el impacto de las elecciones en clave biotech 👉 https://buff.ly/4ftQSO9 🛋️ Temas destacados: 01:00]: Unas elecciones "once in a lifetime" [02:00]: El 50% de las ventas globales en medicamentos ocurre en EE. UU. [05:07]: Comprender la complejidad del sistema sanitario estadounidense [07:50]: Donald Trump VS Kamala Harris [17:05]: El poder de negociación de Medicare [20:06]: ¿El fin de la propiedad intelectual? [22:05]: Estados bisagra o "swing states" [26:56]: El juego de los titulares #YsiosPodcast #BiotechPillsWithJordi #EleccionesEEUU2024 #IndustriaFarmacéutica #Medicare #VentureCapital #SaludGlobal #Innovación

#PortfolioNews I Our #quoted #portfolio company Mineralys Therapeutics, Inc. (NASDAQ: MLYS ) has completed #enrollment in the Launch-HTN #trial ahead of schedule. 🎯Launch-HTN is the second of two trials under the planned pivotal program evaluating the #efficacy and #safety of #lorundrostat for the treatment of uncontrolled #hypertension (uHTN) or resistant hypertension (rHTN). 🔬 The Company expects the trial to be completed earlier than planned, with topline data now anticipated in mid first half of 2025. Full release 👉 https://buff.ly/40oJfUU #ClinicalTrial #Biotech #MedicalInnovation #Healthcare #vc #NASDAQListed

#SPEAKER I Join us for an insightful report presentation on #Europe’s #LifeSciences Future! We're excited to announce that our Partner,  Raúl Martín-Ruiz , will be joining the presentation of the FTI Consulting EU & EUCOPE - European Confederation of Pharmaceutical Entrepreneurs’s latest report: “The Economic Lens: Understanding What Makes the EU Attractive for Life Sciences.” 👉 Registration is open! https://buff.ly/4flgtJa 🗓 14 November ⏰ 16:30 – 18:00 CET 📍 Online via Zoom 🌍Discover how Europe can strengthen its position in the global life sciences sector amidst growing competition. This report presentation will cover the EU's potential to attract life sciences investments, the implications of the proposed pharmaceutical packages, and strategies to boost innovation led by small and mid-sized companies. 🎙 Featured Speakers: - MEP Stine Bossen – Vice-Chair, Subcommittee on Public Health (SANT), European Parliament - Florian Schmidt – Deputy Head of Unit "Medicines: Policy, Authorisation and Monitoring," DG SANTE, European Commission - Raúl Martín-Ruiz – Partner, Ysios Capital - Toon Digneffe – Head of Public Affairs & Public Policy Europe & Canada, Takeda - Alexander Natz – Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs - Antoine Mialhe – Head of Healthcare and Life Sciences, FTI Consulting EU (moderator) #innovation #Science #EuropeanCompetitiveness #HealthcareInvestments #EURegulations #LifeSciences

Reminder to join us this Wednesday at 10:00am ET for a virtual discussion on the unmet medical need in uncontrolled and resistant hypertension and lorundrostat as a potential treatment.   Register here: https://lnkd.in/dtqFfvqf #HighBloodPressure #CVD #Healthcare #Innovation

🎙#Podcast I ¿Aún no has escuchado el último episodio de nuestro podcast mensual? 📡PÍLDORAS DE BIOTECH 💊 Desde el Congreso ESMO - European Society for Medical Oncology 2024 (#ESMO2024), Enric Miquel de Pharma New Talent y Jordi Xiol se unen a la conversación para explorar cómo los descubrimientos más recientes están revolucionando el tratamiento oncológico. ✔️ El papel emergente de China en los ensayos clínicos internacionales. ✔️ Los nuevos fármacos que podrían competir con el gigante Keytruda (Pembrolizumab). ✔️ 10 años de avances en inmunoterapia y mucho más. 🚀 No te pierdas este análisis desde uno de los congresos más importantes del mundo. ¡Dale play y mantente al día en las innovaciones que están marcando la diferencia en #oncología! 🎙 👉 https://lnkd.in/d5pXNXEQ 🛋️ Temas destacados: [0:25]: Un Venture Capital presente en un Congreso de Oncología. [1:30]: ESMO en su contexto: el 2º congreso más importante del mundo. [02:38]: Symposiums presidenciales sin "standing ovations". [04:10]: Biespecíficos: un avance respecto a los anticuerpos monoclonales. [05:30]: Ensayos clínicos "Made in China". [06:20]: Summit Therapeutics: un +270 % en bolsa. [07:11]: ¿Se puede batir a Keytruda (pembrolizumab)?: el fármaco más vendido del mundo, 27 Bn $. [09:59]: BioNTech también realiza ensayos en China. [11:22]: Pfizer aborda la caquexia en pacientes de cáncer. [13:40]: KRAS: diana terapéutica en boga. [14:40]: Balance de 10 años de inmunoterapia en oncología. [15:50]: La evolución profesional dentro de un Venture Capital de Life-Sciences. #YsiosPodcast #BiotechPillsWithJordi #InnovaciónBiotecnológica #Oncología #Ciencia #Salud #PodcastBiotech #BiotechInsights #venturecapital #biotecnología

#PortfolioNews I Our #quoted #portfolio company Aura Biosciences (NASDAQ: AURA )reported positive early data from ongoing Phase 1 #ClinicalTrial of bel-sar (AU-011) in patients with Non-Muscle-Invasive #Bladder #Cancer (NMIBC) 🎯 Bel-sar is a virus-like drug conjugate, designed to have a dual mechanism of action, that induces direct tumor cell necrosis and elicits a robust and durable anti-tumor immune response. Full release 👉 https://buff.ly/3UFZr0H #Phase1Results #Oncology #Biotech #MedicalInnovation #Healthcare #CancerResearch #vc #NASDAQListed

#PortfolioNews I Our #portfolio company Inbiomotion and SPA - Società Prodotti Antibiotici have signed an exclusive agreement for the #MAFTest® in Italy. 🔬 The #MAFTest® aids oncologists in predicting #recurrence and survival rates in #BreastCancer patients and asses potential #eligibility for #bisphosphonate treatment. 🎯 With this agreement, the MAF Test® could potentially increase survival for 8 out of 10 of the 55,000 early-stage breast cancer patients diagnosed annually. 🚀 This agreement follows Inbiomotion’s recent distribution partnerships with Palex España for #Spain and #Portugal, The Scientific Group for Sub-Saharan #Africa and Source BioScience for #UnitedKingdom and #Ireland. Full release 👉 https://buff.ly/3Yew4oi #vc #CancerResearch #Innovation #Spain #oncology